Document 6wd3KLjV70mkVRDw0aj0dqB4

From: Sent: To: Cc: Subject: Attachments: FYI   (CAB-KYRIAKIDES) mercredi 1 juillet 2020 11:14 (CAB-KYRIAKIDES); (CAB- KYRIAKIDES); (CAB-KYRIAKIDES); (CAB-KYRIAKIDES) (CAB-KYRIAKIDES) Report from meeting with Endocrine Society (cancer, chemicals) BTO ED society 30062020.doc EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL   Brussels, 30 June 2020 MEETING WITH THE ENDOCRINE SOCIETY EDC ADVISORY GROUP COUNTERPART SANTE WHERE, WHEN SUBJECT OBJECTIVE OF THE MEETING RESULT Commissioner Kyriakidis, Kyriakides) (DG SANTE E2) ueller, (CAB- Via videoconference, Tuesday 20 June 2020 Endocrine Disruptors (EDs) On request of the Endocrine Society as regards their position on the science of EDs and their regulation in the EU The Group presented themselves and the context in which they requested the meeting. In general they have been encouraged by the commitment given from Commissioner Kyriakidis on EDs and wish to offer their scientific expertise. They have already submitted comments to the Commission's ED Fitness Check exercise and to the Chemicals Strategy roadmap. They presented a Powerpoint (see annex) putting forward their concerns on exposures to EDs and health effects, gaps in EU regulation and the need for immediate action to protect consumers. In particular they promoted inclusion of EDs in the EU Cancer Plan given links with prostate and breast cancers; the need to harmonise more sectors beyond pesticides and biocides including addressing food contact materials (FCMs) and cosmetic; and the links with increased vulnerability of immune-deficient individuals and other illnesses that may be linked with EDs during times of pandemic such as COVID-19. They emphasised the important aspects they consider on EDs such as low-dose, nonmonotonic effects and cumulative exposures. The impact on vulnerable populations including children, babies and pregnant women was also highlighted as were the roles that EDs can play in diseases such as cancer, growth issues, neurodevelopmental issues, diabetes and metabolic diseases, where they consider presence of EDs exacerbate the effects of diet, including for example sugar. They presented a table included in the report on EDs commissioned by the Parliament's PETI committee for which Barbara Demeneix was an author, giving an overview of where they consider gaps in the current EU regulatory framework. They consider that classification in the CLP Regulation and thus identification would make it easier to regulate EDs in downstream legislation such as cosmetics and FCMs where they consider their presence unjustified. They consider EU action even more important in the global context, where third countries follow the EU approach. Commissioner Kyriakidis thanked the participants and that the Commission shares their ambitions for a horizontal and harmonised approach, which will be addressed under the Chemicals Strategy. In this respect, the Society was encouraged to also put across its views to Commissioners Sinkeviius and Breton, who also have responsibility for this issue. Commissioner Kyriakidis agreed that EDs should be considered in the Cancer Plan and referred to the substantial additional budget set aside FOLLOW-UP for the EU4Health initiative, which also focuses on non-communicable diseases. Endocrine Society will aim to speak with Commissioner Breton (having already met Sinkeviius) and were asked to send any more relevant information as soon as possible. Annex Endocrine Society presentation +HDOWK&RPPLVVLR 6OLG ),1$/ 2